Teva scores European patent victory for long-acting Copaxone

Carly Helfand

After fighting a long battle over the IP shield on lead drug ,  is feeling the heat from generics makers over the on its new, long-acting version of the drug. Monday, though, it got some good news in Europe that'll keep knockoffs makers at bay–for now.


FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS